Cagrilintide
A long-acting amylin analogue developed to complement GLP-1 weight-loss therapy.
How it works
Cagrilintide binds amylin and calcitonin receptors, slowing gastric emptying and engaging hindbrain satiety circuits via a mechanism complementary to GLP-1.
Reported benefits
- Up to 10.8% weight loss in 26 weeks as monotherapy
- Additive 17% loss when combined with semaglutide 2.4 mg (CagriSema)
- Lower nausea profile than GLP-1 alone in some protocols
Dosage & administration
Phase-2 escalated weekly from 0.3 mg to 4.5 mg.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Cagrilintide for obesity, dose-finding trial
The Lancet · 2021
706 adults; 4.5 mg weekly produced 10.8% mean weight reduction at 26 weeks.
Safety & warnings
- GI symptoms milder than GLP-1 agonists
- Injection-site reactions possible
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
CGL5
Box of 10 · $351
Single vial · $702
10 mg
CGL10
Box of 10 · $681
Single vial · $1,362
Related guides
Tirzepatide
A first-in-class dual GIP and GLP-1 receptor agonist that has reset the standard for pharmacologic weight loss.
Semaglutide
The long-acting GLP-1 analogue that opened the modern era of injectable weight management.
Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing unprecedented weight loss in phase-2 data.